Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2007

View Archived Issues

ABT-737 sensitizes AML cells to Flt3 inhibitor

mGluR2/3 antagonist LY-341495 exerts antidepressant activity in rodents

Rhein Biotech shareholders approve merger with Berna Rhein

Oncolytics Biotech begins new Reolysin studies

Azilect disease modification study in early Parkinson's completes enrollment

S-7701 significantly inhibits worsening of IPF in Japanese studies

Zadaxin plus DTIC improves survival in stage IV malignant melanoma

Grazax shows improved effect in second treatment season of study

Encouraging results for removab in malignant ascites in ovarian cancer patients

Insulin resistance may result from impaired cytohesin function

AstraZeneca to continue development of AZD-3480

CoFactor and 5-FU studied in refractory metastatic breast cancer

ThromboGenics and BioInvent receive funding for antiangiogenesis program

Omrix highlights Q4 milestones

Sunitinib filed in Japan for renal carcinoma and gastrointestinal stromal tumors

Vectura signs U.S. collaboration for VR-315 combination asthma therapy

Phase III Zadaxin triple therapy study in HCV completes enrollment

KSP inhibitor ARRY-520 to begin clinical testing

Sirna shareholders approve acquisition by Merck & Co.

Bioenvision prepares MAA for Evoltra in AML

KRX-0401 studied with Revlimid and dexamethasone for multiple myeloma

FDA accepts complete response to Thelin NDA

Novel analgesic agents revealed in recent patents

Molecular function of Cdk5 in pain signaling elucidated

Recent patents describe novel agents for metabolic disorders

Novel compounds discovered with potential use in neurological disorders

Approvable letter for Pennsaid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...